CD19 and B-cell non-Hodgkin lymphoma: Agents such as 5-aza-2’-deoxycytidine increase the expression of the antigen CD19 on the surface of lymphoma cells, and patients with B-cell lymphoma are more susceptible to CD19 CAR-T cells (32).